AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01735877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
Study NCT01735877 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
Study NCT00802230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline Infusion
Study NCT02034929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoCuff-assisted colonoscopy
Description: EC-assisted colonoscopy
Study NCT02034929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy
Study NCT01290068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL
Description: Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
Study NCT03827785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS treatment group
Description: For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.
Study NCT03827785 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment group
Description: For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.
Study NCT01290068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study NCT01290068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal IOL
Description: Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
Study NCT00395629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Study NCT03841565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03841565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03841565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (post-operative)
Description: Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
Study NCT03374150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet counseling
Description: Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
Study NCT03374150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet counseling
Description: Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin (post-operative)
Description: Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (post-operative)
Description: Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
Study NCT01503905 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
Study NCT02112812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication therapy for H.pylori infection
Description: Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
Study NCT02112812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication of Helcobacter Pylori
Description: Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin （post-operative)
Description: Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
Study NCT02112812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication therapy for Helicobacter pylori
Study NCT01869712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (post-operative)
Description: After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
Study NCT01869712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study NCT02313012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90003
Description: CC-90003 PO once daily
Study NCT02458105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy
Description: A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
Study NCT02458105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention
Description: Supportive conversation at a frequency and length corresponding to the experimental condition.
Study NCT01617629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Dendritic Cell Vaccine (Cvac)
Description: The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks).
Study NCT00194922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: E. Coli Strain M17 Probiotic
Description: 30 ml PO BID for 12 weeks
Study NCT02228213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MIS416
Description: Intravenous administration weekly for 52 weeks
Study NCT02228213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous administration weekly for 52 weeks
Study NCT04532892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meta 18.06 Day and Meta 18.06 Night
Description: 5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
Study NCT04532892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Meta 18.06 Day and Placebo Meta 18.06 Night
Description: 5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
Study NCT02276482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phophate
Description: Tedizolid Phophate 200 mg, IV and/or oral for 6 days
Study NCT02276482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic comparator
Description: Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
Study NCT02276482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
Study NCT02276482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam
Description: In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
Study NCT02276482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
Study NCT02276482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
Study NCT04045457 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: dry needling
Description: insertion of needle into active myofascial trigger point
Study NCT02267382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161
Study NCT02267382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04619641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula (HFNC)
Description: HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
Study NCT04619641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet
Study NCT00113438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
Description: Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
Study NCT02590718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optimized postoperative management
Description: lying without the pillow for half an hour after lumbar puncture
Study NCT01891006 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard wound dressing
Description: The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
Study NCT01532830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: n-VNS
Study NCT01662661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 (suspension)
Description: Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
Study NCT01662661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 (tablet)
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
Study NCT04351100 — intervention group
Intervention type: DRUG
Intervention: Diacerein
Description: Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
Study NCT03127475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT03127475 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT03452735 — intervention group
Intervention type: OTHER
Intervention: Questionnaire about fertility
Description: Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
Study NCT04625023 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Retrospective cohorts and Prospective observation of standard clinical practice
Study NCT02815709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Study NCT03538535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go/No-Go Active Learning (GOAL)
Description: Behavioral Activation psychotherapy adapted to engage go/no-go learning
Study NCT03943095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate
Description: The test dentifrice contains 5% w/w potassium nitrate.
Study NCT03943095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride
Description: The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
Study NCT03943095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
Study NCT00768274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice daily (b.i.d.) for 28 days
Study NCT00768274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo twice daily (b.i.d.) for 28 days
Study NCT01674036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-682452
Description: Capsules for oral administration.
Study NCT01674036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Genz-682452
Study NCT01308216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy procedure
Description: Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
Study NCT01308216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low level laser therapy procedure
Description: Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
Study NCT03143218 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RABIPUR®
Description: Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
Study NCT03143218 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01
Description: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
Study NCT03143218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC with SP+AQ
Description: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
Study NCT03143218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC placebo
Description: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
Study NCT04596254 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pomegranate Juice
Description: Collection of Mother's milk before and after juice consumption
Study NCT02815709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03177304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based IPT Training
Study NCT03448146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-Toluenesulfonamide
Study NCT04697758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.1 mg
Description: Single intravitreal injection of AXT107 0.1 mg/eye
Study NCT04697758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.25 mg
Description: Single intravitreal injection of AXT107 0.25 mg/eye
Study NCT04697758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.5 mg
Description: Single intravitreal injection of AXT107 0.5 mg/eye
Study NCT02475408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug
Study NCT02815709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT00139659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin
Description: Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Study NCT00139659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Study NCT03599934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle integrated functional exercise program
Description: Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
Study NCT03599934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home safety assessment
Description: Home safety assessment and modification that targets to reduce environmental risk factors of falls.
Study NCT03548272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention with stent implantation
Description: PCI with BiOSS LIM C or rDES depending on the randomization
Study NCT03548272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention with stent implantation
Description: PCI with BiOSS LIM C or rDES depending on the randomization
Study NCT03317288 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dabir Air overlay
Description: The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
Study NCT03856645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKG-0301
Description: OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
Study NCT03856645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OKG-0301
Description: OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
Study NCT02653066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealtheRx+
Description: Participant receives $5 bill with incentive check and blank consent form